Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Radiation Oncology
•
Medical Oncology
•
Breast Cancer, Non-metastatic
How would a diagnosis of porphyria cutanea tarda impact your treatment recommendations in early stage breast cancer?
Would it impact your (neo)adjuvant systemic therapy or radiation therapy approach?
Related Questions
How do you respond to a patient who asks "Why do I still need breast radiation after chemotherapy if chemotherapy treats the whole body?"
In light of the NSABP B51 data presented at SABCS, will you defer RNI in all patients with negative nodes after chemotherapy?
What are your top takeaways in Breast Cancer from ASCO 2023?
Can you safely proceed with breast irradiation during treatment with immunotherapy?
In a patient with local recurrence of breast cancer after mastectomy, how would you sequence adjuvant treatment after wide local resection?
How do you approach the discussion with a patient who is seeking proton therapy for early stage breast cancer?
How would you approach a cT4 cN2 (22 cm in size) TNBC that shrank to 9 cm with KN-522 regimen but remains inoperable at the end of treatment?
For which patients, if any, do you typically order additional imaging workup for staging in early-stage breast cancer?
What are your top takeaways from SABCS 2023?
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?